The estimated Net Worth of Catherine Bollard is at least $193 Tausend dollars as of 18 October 2022. Catherine Bollard owns over 1,000 units of Cabaletta Bio Inc stock worth over $4,260 and over the last 3 years he sold CABA stock worth over $0. In addition, he makes $188,866 as Independent Director at Cabaletta Bio Inc.
Catherine has made over 1 trades of the Cabaletta Bio Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of CABA stock worth $990 on 18 October 2022.
The largest trade he's ever made was buying 1,000 units of Cabaletta Bio Inc stock on 18 October 2022 worth over $990. On average, Catherine trades about 200 units every 0 days since 2021. As of 18 October 2022 he still owns at least 1,000 units of Cabaletta Bio Inc stock.
You can see the complete history of Catherine Bollard stock trades at the bottom of the page.
Dr. Catherine Bollard M.D. serves as Independent Director of the Company. She is the director of the Center for Cancer and Immunology Research at the Children’s Research Institute and the director of the Program for Cell Enhancement and Technologies for Immunotherapy at the Children’s National Health System, or CNHS. She is also a member of the Division of the Blood and Marrow Transplantation of CNHS. Since 2013, Dr. Bollard also serves as Professor of Pediatrics and Microbiology, Immunology and Tropical Medicine at the George Washington University and is the associate center director for translational research and innovation within the George Washington Cancer Center. Prior to her move in 2013, Dr. Bollard was Professor of Pediatrics, Medicine and Immunology at Baylor College of Medicine. She is the immediate past president of the International Society for Cell Therapy, and she served on the Cellular, Tissues and Gene Therapy Advisory Committee of the FDA until 2019. Dr. Bollard has chaired the Non-Hodgkin’s Lymphoma Committee of the Children’s Oncology Group since 2012 and previously served as a member of the board of directors of the Foundation for the Accreditation of Cellular Therapy. Dr. Bollard received her medical degree from University of Otago Medical School in New Zealand.
As the Independent Director of Cabaletta Bio Inc, the total compensation of Catherine Bollard at Cabaletta Bio Inc is $188,866. There are 8 executives at Cabaletta Bio Inc getting paid more, with Anup Marda having the highest compensation of $1,528,630.
Catherine Bollard is 52, he's been the Independent Director of Cabaletta Bio Inc since 2019. There are 7 older and 7 younger executives at Cabaletta Bio Inc. The oldest executive at Cabaletta Bio Inc is Richard Henriques, 64, who is the Independent Director.
Catherine's mailing address filed with the SEC is C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA, PA, 19104.
Over the last 5 years, insiders at Cabaletta Bio Inc have traded over $19,324,000 worth of Cabaletta Bio Inc stock and bought 1,500,545 units worth $13,043,398 . The most active insiders traders include Group, Llc Green Jeremy Red..., Ventures V, L.P.5 Am Opport... und James E Deerfield Mgmt Iv, .... On average, Cabaletta Bio Inc executives and independent directors trade stock every 70 days with the average trade being worth of $632,329. The most recent stock trade was executed by Gwendolyn Binder on 19 January 2024, trading 11,000 units of CABA stock currently worth $11,110.
cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un
Cabaletta Bio Inc executives and other stock owners filed with the SEC include: